Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2007

01-10-2007 | Review

The safety profile of drotrecogin alfa (activated)

Authors: Roberto Fumagalli, Mariano A Mignini

Published in: Critical Care | Special Issue 5/2007

Login to get access

Abstract

Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safety analyses since 1995. However, the only comprehensive review of all trials is that reported in 2003 by Bernard and coworkers. This is an important review that focuses on the safety profile of DrotAA in all published studies (six randomized clinical trials and five national registry studies) and in previously unpublished data. DrotAA treatment is associated with an increased risk for bleeding (which in general is manageable). Nevertheless, the available evidence shows that any adverse effects of DrotAA are outweighed by its benefits in patients with severe sepsis who are at high risk for death. So far, more than 9,000 patients have been enrolled in clinical trials involving DrotAA, providing a valuable safety database. It is of note that although DrotAA does increase the risk of bleeding, this has not been associated with an overall increase in the rate of all severe adverse events.
Literature
1.
Marlar RA, Kleiss AJ, Griffin JH: Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci 1981, 370: 303-310. 10.1111/j.1749-6632.1981.tb29743.xCrossRefPubMed
2.
Esmon CT: The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun 2000, 15: 113-116. 10.1006/jaut.2000.0400CrossRefPubMed
3.
Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JMS: New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005,9(Suppl 4):38-45. 10.1186/cc3747CrossRef
4.
Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003, 373: 65-70. 10.1042/BJ20030341PubMedCentralCrossRefPubMed
5.
Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007, 109: 3161-3172. 10.1182/blood-2006-09-003004CrossRefPubMed
6.
7.
8.
9.
Short MA, Schlichting D, Qualy R: From bench to bedside: a review of the clinical trial development of drotrecogin alfa (activated). Curr Med Res Opin 2006, 22: 2525-2540. 10.1185/030079906X154060CrossRefPubMed
10.
Bernard GR, Ely EE, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, on behalf of the rhAPC Sepsis Study Group, et al.: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003CrossRefPubMed
11.
Bernard GR, Vincent J-L, Laterre P-F, La Rosa SP, Dhainaut J-F, Lopez Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis PROWESS) Study Group, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
12.
Vincent J-L, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut J-F, Artigas A, Fumagalli R, Macias WL, Wright T, for the ENHANCE Study Group, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33: 2266-2277. 10.1097/01.CCM.0000181729.46010.83CrossRefPubMed
13.
Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 10.1056/NEJMoa050935CrossRefPubMed
14.
Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, for the Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group, et al.: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176: 483-490. 10.1164/rccm.200612-1803OCCrossRefPubMed
15.
Sharshar T, Annane D, de la Grandmaison GL, Brouland JP, Hopkinson NS, Francoise G: The neuropathology of septic shock. Brain Pathol 2004, 14: 21-33.CrossRefPubMed
16.
Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent J-L: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7: 155-163. 10.1186/cc2167PubMedCentralCrossRefPubMed
17.
Rowan K, Welch CA, North E, Harrison DA: Multicenter audit of the use of drotrecogin alfa (activated) in United Kingdom critical care units [abstract 375]. Intensive Care Med 2006,32(suppl 1):99.
18.
Vincent JL, Laterre PF, Janes J, Nelson D, Haentjens T, Sartral M, Ermens M, Sundin D: Analysis of drotrecogin alfa (activated) use in Belgium: comparison to PROGRESS registry data [abstract 227]. Intensive Care Med 2005,31(suppl 1):62.
19.
Kübler A, Mayzner-Zawadzka E, Durek G, Gaszyñski W, Karpel E, Mikaszewska Sokolewicz M, Majak P: Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit 2006, 12: CR107-CR112.PubMed
20.
Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D: Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 2007, 33: 426-434. 10.1007/s00134-007-0554-xCrossRefPubMed
21.
Kanji S, Perreault MM, Chant C, Williamson D, Burry L: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 2007, 33: 517-523. 10.1007/s00134-007-0555-9CrossRefPubMed
22.
Barie PS, Hydo LJ, Shou J, Eachempati SR: Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect (Larchmt) 2006,7(suppl 2):S77-S80.
23.
Laterre P-F, Wittebole X: Clinical review: drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification. Crit Care 2003, 7: 445-450. 10.1186/cc2342PubMedCentralCrossRefPubMed
24.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, for the REsearching severe Sepsis and Organ dysfunction in children, et al.: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 2007, 369: 836-843. 10.1016/S0140-6736(07)60411-5CrossRefPubMed
25.
Mann HJ, Demmon SL, Boelk DA, Payne CA, Effron MB, Rajagopalan N, Williams MD, Beck GM, Gopalrathnam G: Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. Am J Health Syst Pharm 2004, 61: 2664-2671.PubMed
26.
Lee SJ, Schuster R, Bindewald M, Greaney G, Waxman K: Second course of recombinant human activated protein C delivered to a severely septic patient after recent surgery. Trauma 2006, 61: 1-3.CrossRef
27.
Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999, 25: 63-67. 10.1007/s001340050788CrossRefPubMed
28.
Vincent JL: Drotrecogin alfa (activated) in the treatment of severe sepsis. Expert Rev Anti Infect Ther 2006, 4: 537-547. 10.1586/14787210.4.4.537CrossRefPubMed
29.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, for the KyberSept Trial Study Group, et al.: High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRefPubMed
30.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Lopez Rodriguez A, Beale R, Svoboda P, Laterre P-F, Simon S, for the OPTIMIST Trial Study Group, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA 2003, 290: 238-247. 10.1001/jama.290.2.238CrossRefPubMed
31.
Laterre PF, Abraham E, Janes J, Trzaskoma BL, Correll NL, Booth FV: ADDRESS (ADministration of Drotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Crit Care Med 2007, 35: 1457-1463. 10.1097/01.CCM.0000266588.95733.63CrossRefPubMed
32.
Williams MD, Macias W, Rustige J: Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Med 2007, 33: 1487-1488. 10.1007/s00134-007-0709-9CrossRefPubMed
33.
34.
Plataki M, Vaporidi K, Georgopoulos D: Is there increasing evidence that the risks of rhAPC may outweigh its benefits? Intensive Care Med 2007, 33: 1485-1486. 10.1007/s00134-007-0707-yCrossRefPubMed
Metadata
Title
The safety profile of drotrecogin alfa (activated)
Authors
Roberto Fumagalli
Mariano A Mignini
Publication date
01-10-2007
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 5/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6157

Other articles of this Special Issue 5/2007

Critical Care 5/2007 Go to the issue

Review

The protein C pathway: implications for the design of the RESPOND study

Review

Diagnosis and treatment of severe sepsis

Review

Recombinant human activated protein C: current insights into its mechanism of action

Introduction

Introduction: severe sepsis and drotrecogin alfa (activated)

Review

Practical aspects of treatment with drotrecogin alfa (activated)

Review

Clinical trials in severe sepsis with drotrecogin alfa (activated)